Indication

CD30-positive mycosis fungoides

CD30-positive mycosis fungoides is a subtype of mycosis fungoides—the most common form of cutaneous T-cell lymphoma—distinguished by the immunohistochemical expression of the cell-surface marker CD30 on malignant T lymphocytes. Read more about CD30-positive mycosis fungoides

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common CD30-positive mycosis fungoides therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with CD30-positive mycosis fungoides preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About CD30-positive mycosis fungoides.

CD30-positive mycosis fungoides is a subtype of mycosis fungoides—the most common form of cutaneous T-cell lymphoma—distinguished by the immunohistochemical expression of the cell-surface marker CD30 on malignant T lymphocytes.

It primarily targets the skin in adult populations and may manifest across disease stages as persistent patches, indurated plaques, or cutaneous tumors, often arising during large-cell transformation or in advanced progression.

Pathophysiologically, epidermotropic and dermal malignant helper T cells upregulate this tumor necrosis factor receptor superfamily member, providing a defined biomarker that differentiates it from typical CD30-negative presentations and indicates potential susceptibility to CD30-directed therapies.

Personalize your experience

Follow CD30-positive mycosis fungoides and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it